Long-term Efficacy and Safety of HMS5552 in T2DM Subjects

Summary

This study evaluates the efficacy and safety and population PK of HMS5552 as monotherapy in adult type 2 diabetic subjects, there will be 2 groups in the first 24 weeks, one group will receive HMS5552 , while the other group will receive placebo ; after 24 weeks, all subjects will receive HMS5552 for 28 weeks.

Timeline

Start

2017-07-18

Primary completion

2020-11-30

Completion

2020-11-30

Drugs

Indications